NCT00913224

Brief Summary

To demonstrate the relative bioavailability of Diclofenac Sodium 50 mg enteric-coated tablets.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Apr 1993

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 1993

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 1993

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 1993

Completed
16.2 years until next milestone

First Submitted

Initial submission to the registry

June 2, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 4, 2009

Completed
Last Updated

March 28, 2017

Status Verified

June 1, 2009

Enrollment Period

Same day

First QC Date

June 2, 2009

Last Update Submit

March 27, 2017

Conditions

Inflammation

Keywords

Anti-inflammatory

Outcome Measures

Primary Outcomes (1)

  • Bioequivalence based on AUC and Cmax

    17 days

Study Arms (2)

1

EXPERIMENTAL

Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)

Drug: Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)

2

ACTIVE COMPARATOR

Voltaren 50 mg Tablets (Geigy Pharmaceuticals)

Drug: Voltaren 50 mg Tablets (Geigy Pharmaceuticals)

Interventions

Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)DRUG
1
Voltaren 50 mg Tablets (Geigy Pharmaceuticals)DRUG
2

Eligibility Criteria

Age18 Years - 41 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

You may not qualify if:

  • Positive test results for HIV or hepatitis B or C.
  • Treatment for drug or alcohol dependence.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Inflammation

Interventions

Diclofenac

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PhenylacetatesAcids, CarbocyclicCarboxylic AcidsOrganic Chemicals

Study Officials

  • Paul D. Larsen, M.D.

    Red River Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

June 2, 2009

First Posted

June 4, 2009

Study Start

April 1, 1993

Primary Completion

April 1, 1993

Study Completion

April 1, 1993

Last Updated

March 28, 2017

Record last verified: 2009-06